Seroprevalence of hepatitis A virus in Mumbai, and immunogenicity and safety of hepatitis A vaccine.

Simple item page
dc.contributor.authorDhawan, P Sen_US
dc.contributor.authorShah, S Sen_US
dc.contributor.authorAlvares, J Fen_US
dc.contributor.authorKher, Aen_US
dc.contributor.authorShankaran,en_US
dc.contributor.authorKandoth, P Wen_US
dc.contributor.authorSheth, P Nen_US
dc.contributor.authorKamath, Hen_US
dc.contributor.authorKamath, Aen_US
dc.contributor.authorKoppikar, G Ven_US
dc.contributor.authorKalro, R Hen_US
dc.date.accessioned1998-01-18en_US
dc.date.accessioned2009-05-29T03:36:40Z
dc.date.available1998-01-18en_US
dc.date.available2009-05-29T03:36:40Z
dc.date.issued1998-01-18en_US
dc.description.abstractOBJECTIVES: Since epidemiologic trends of hepatitis A are changing worldwide, we studied its seroprevalence in Mumbai, which is thought to be a high-endemicity area. The immunogenicity and safety of a hepatitis A vaccine were also studied. METHODS: Six hundred and seventy subjects (456 men; age range 6 mo-60 y) answered a questionnaire on social and medical history. Qualitative analysis of total anti-HAV was performed in all subjects by ELISA. One hundred and seven of 147 anti-HAV negative subjects received hepatitis A vaccine at months 0, 1 and 6. Subjects were followed up (months 1, 2, 6, 7) to look for side-effects and seroconversion. RESULTS: The seroprevalence of HAV was 523/670 (78%); 38% of children < 5 years were anti-HAV negative. Seroprevalence rates of 80% were reached by 15 years. Prevalence was lower in the higher socio-economic group (151/234; 64.5%) compared with the lower socio-economic group (372/436; 85%) (p < 0.001). One month after doses 1, 2 and 3 of the hepatitis A vaccine, seropositivity was 92%, 99% and 100%, respectively. Minor self-limited side-effects occurred in 19.5% of subjects; there were no major side-effects. CONCLUSIONS: The seroprevalence of anti-HAV is high in Mumbai. Seroprevalence is lower in the higher socio-economic groups. The hepatitis A vaccine is safe and immunogenic.en_US
dc.description.affiliationDepartment of Gastroenterology, BYL Nair Hospital, Mumbai.en_US
dc.identifier.citationDhawan PS, Shah SS, Alvares JF, Kher A, Shankaran , Kandoth PW, Sheth PN, Kamath H, Kamath A, Koppikar GV, Kalro RH. Seroprevalence of hepatitis A virus in Mumbai, and immunogenicity and safety of hepatitis A vaccine. Indian Journal of Gastroenterology. 1998 Jan; 17(1): 16-8en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/65542
dc.language.isoengen_US
dc.source.urihttps://www.indianjgastro.comen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshHepatitis A --epidemiologyen_US
dc.subject.meshHepatitis A Virus, Human --immunologyen_US
dc.subject.meshHepatitis Antibodies --analysisen_US
dc.subject.meshHumansen_US
dc.subject.meshIndia --epidemiologyen_US
dc.subject.meshInfanten_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshSafetyen_US
dc.subject.meshSocioeconomic Factorsen_US
dc.subject.meshViral Hepatitis Vaccines --adverse effectsen_US
dc.titleSeroprevalence of hepatitis A virus in Mumbai, and immunogenicity and safety of hepatitis A vaccine.en_US
dc.typeJournal Articleen_US
dc.typeResearch Support, Non-U.S. Gov'ten_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Indian Journal of Gastroenterology